![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer (VJOncology) View |
![]() |
TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer (EMJ) View |
![]() |
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer (GRACE - Global Resource for Advancing Cancer Education) View |
![]() |
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer (Raquel Vasquez) View |
![]() |
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer (ecancer) View |
![]() |
Third-Generation EGFR Inhibitors in NSCLC (OncLive) View |
![]() |
Third-Generation EGFR Inhibitors in NSCLC (OncLive) View |
![]() |
DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib (HMP Education) View |
![]() |
Patient Selection for Osimertinib; Thoughts on Sequencing (Targeted Oncology) View |
![]() |
DEBATE: Molecular profiling beyond EGFR/ALK - Must be the standard (HMP Education) View |